{'fraction_non_alphanumeric': 0.01602136181575434, 'fraction_numerical': 0.0, 'mean_word_length': 6.0754716981132075, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The kinetics of the interaction of heterologous anti-tumor serum and heterologous complement in non-tumor bearing mice.

The persistence of heterologous antitumor serum in the periphery of normal, non-tumor bearing mice was analyzed following intravenous, intraperitoneal, and subcutaneous injection. Intravenous injection of guinea pig complement subsequent to antibody administration resulted in the immediate disappearance of tumor-specific antibody from the periphery. Such studies suggest that appropriate therapy by the passive administration of antiserum requires the initial administration of antibody to allow for preferential binding to tumor-specific antigens followed by the subsequent injection of complement to mediate tumor cytolysis.